Could an antibody fight both psoriasis and heart disease?
Disease control
Completed
This phase 2 trial tested a drug called orticumab in 77 adults with moderate-to-severe psoriasis who also had cardiometabolic risks (like obesity and high cholesterol). The goal was to see if orticumab could safely reduce skin plaques and inflammation linked to heart disease. Par…
Phase: PHASE2 • Sponsor: Abcentra • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC